Who is the CEO of Kymera Therapeutics?

Who is the CEO of Kymera Therapeutics?

Nello Mainolfi, PhD | Kymera Therapeutics. Founder, President & CEO Nello is Founder, President, and Chief Executive Officer of Kymera Therapeutics.

How many employees does Kymera Therapeutics have?

Kymera Therapeutics has 208 employees What industry does Kymera Therapeutics belong to? Kymera Therapeutics, Inc.The gross proceeds to Kymera from the offering are expected to be approximately $250. Kymera, excluding the exercise of any pre-funded warrants and assuming no exercise of the underwriters’ option to purchase .We are excited to work with the talented Gilead team to accelerate the development and commercialization of this important program. Under the terms of the agreement, Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments.

What does Kymera Therapeutics do?

Kymera is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera Therapeutics’ headquarters are located at 500 North Beacon Street, 4th Floor, Watertown, MA 02472.About Kymera Therapeutics Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www. X or LinkedIn.Kymera Therapeutics’s competitors and similar companies include Foghorn Therapeutics, XBiotech, Adicet Bio and Jnana.Kymera is a clinical-stage biotechnology company working to reinvent the treatment of human disease through the development of innovative, highly differentiated medicines that address critical health problems and dramatically improve patients’ lives.

When was Kymera founded?

Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts. At Kymera International, safety, innovation and continuous improvement are at the heart of everything we do. This commitment is exemplified by our employees, who consistently strive to make our processes more efficient, safer, and more effective.

How big is Kymera Therapeutics?

The current market capitalization of Kymera Therapeutics is $3. B. The average price target for Kymera Therapeutics is 61. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $70. The average price target represents 33. Increase from the current price of $45.Average Price Target Based on 8 Wall Street analysts offering 12 month price targets for Alexandria Equities in the last 3 months. The average price target is $97. The average price target represents a 24.The highest analyst price target is $3. The average price target represents -16. Decrease from the current price of $3. Revance Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 3 Wall Streets Analysts.

When did Kymera Therapeutics go public?

WATERTOWN, Mass. June 26, 2025 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. Kymera is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top